Monday 1st December – Day 1 Main Conference - GMT (Greenwich Mean Time, GMTZ)
- Catherine Simpson - Conference Director - Cell and Gene Therapy Portfolio, Informa Connect LifeSciences
- Marion Hitchcock - Managing Director Gene & Cell Therapies Incubator Berlin, Bayer
Starting from a brownfield and a greenfield, 2 brand new facilities for CAR-T production were built in Ghent in 2-3 years’ time. Building up the facility, recruiting and training people, building and qualifying processes and systems, passing HA inspections, meeting customer’s needs, an amazing experience for all involved.
- Frederik Buysse - VP-General Manager EU, Legend Biotech
- Snapshot into the investment landscape for CGT products and enabling technologies: Our expert investors reveal their bold predictions for CGT's trajectory through 2026
- Uncover game-changing investment opportunities in CGT as leading investors reveal which technologies are poised to disrupt healthcare and deliver exceptional returns
- Standing out in the crowd: Positioning for success in a competitive funding environment: What do investors need to see?
“Ask the Investor” interactive Q&A open discussion with our investor panel to get tips and tricks when pitching and their views on where innovation lies in the CGT field
- Bo Wiinberg - Chief Business Development Officer, Novo Nordisk Foundation Cellerator
- Matthieu Coutet - Partner, Sofinnova Partners
- Therese Liechtenstein - Investment Director, 4BIO Capital
- Christian Uhrich - Executive Investment Director, Biotechnology Investments, M Ventures
- Ole Henrik Bang-Andreasen - Principal, Avant Bio
- Artemy Shumskiy - Senior Associate, LongeVC
- Stijn Heessen - Co-founder, COO, Alder Therapeutics AB
- Jan Spanholtz - CSO, Glycostem Therapeutics
- Anette Brass - Head of Process Development, Anocca
- Dethardt Müeller - Chief Technology Officer - CMC, Abalos Therapeutics GmbH
- Hiroyuki Usuda - Scouting & Transaction Lead, Business Development, Astellas Pharma Europe Ltd
- Larry Forman - Founder and CEO, CHO Plus, Inc.
- Giovanni Ganendra - Upstream Process Science Senior Scientist, UCB
Visit BioLife Solutions during the Live Lab tour. BioLife Solutions is a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. During this presentation, we will discuss impact of cell culture ancillary materials on cell health and performance, highlight downstream fill/finish and primary packaging considerations as well as present some information around optimisation of biopreservation.
Join the Terumo Blood and Cell Technologies Live Lab session and discover how the Quantum Flex™ Cell Expansion System can help you simplify, de-risk, and accelerate your cell expansion journey—from process development through to commercial manufacturing.
Visit KyooBe during the Live Lab tour and explore our innovative cube-based production approach for cell and gene therapies. Our cubes are mobile aseptic units that integrate seamlessly with isolators for safe, segregated batch production. Experience how closed modular design and automation bring flexibility, safety, and efficiency to personalized medicine.
- Andrea Gaißler - Research Associate, Fraunhofer Institute for Manufacturing Engineering and Automation IPA
- Lindsay Davies - Chief Scientific Officer, NextCell Pharma
- Olivia Candini - Head of Process Development, Cell & Gene Therapy, Evotec Modena
- Julie Aubert - DSP Development Engineer, Généthon
- Mirjana Cvijanovic - Scientific Sr. Manager, Johnson & Johnson
Explore groundbreaking research, meet the poster presenters and ask your questions.
- Marina Tarunina - Research Director, Plasticell Ltd
- Fabien Dorange - Director Analytical Sciences, SparingVision
- Hiroyuki Usuda - Scouting & Transaction Lead, Business Development, Astellas Pharma Europe Ltd
- Markus Haindl - Global Head Gene Therapy Technical Research & Development, Roche-Genentech